Rituximab Offers No Benefit Over Placebo to Patients With Active or Moderate-to-Severe Graves' Orbitopathy | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Rituximab Offers No Benefit Over Placebo to Patients With Active or Moderate-to-Severe Graves’ Orbitopathy


Prevention of Graves’ orbitopathy (GO) remains an elusive goal. To date, there is no effective measure to prevent GO, a potentially sight-threatening disease. Some patients with mild disease benefit from selenium treatment, but other systemic therapies are generally not offered due to potential adverse effects. Intravenous corticosteroids, helpful for the inflammatory signs and symptoms of GO, are associated with significant adverse effects. Treatment requires repeated infusions over many weeks and nearly 30 percent of patients relapse.

Orbital decompression, a complex surgical procedure, is typically offered when the disease is severe, other treatment modalities have failed or inactive disease requires rehabilitative surgery. 

A literature review published by Mario Salvi, M.D., and others in The Journal of Clinical Endocrinology & Metabolism in 2013 suggests that rituximab may benefit patients with GO. Rituximab is a humanized chimeric anti-CD20 monoclonal antibody that depletes both B lymphocytes in the intermediate stages of maturation and short-lived plasma cells.

Rituximab Offers No Benefit Over Placebo To Patients With Active Or Moderate-to-Severe Graves’ Orbitopathy
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close